Tag Archives: drugs

Big gainers with no news (VTCN, CLVS, HDY, CISG, HNSN)

Posted on January 19, 2012 by Martin Timble

Some of the following stocks have seen strong gains during Thursday’s session with no news.

Hansen Medical (NASDAQ:HNSN) gained more than 15 percent on Thursday. The medical appliance and equipment maker also seen an unusually high amount of volume pass …

Posted in Latest Headlines, Reports | Tagged average, biotech, CISG, CNinsure, drugs, exploration, freight, Hansen Medical, HNSN, insurance broker, market, medical appliance, NASDAQ, NASDAQ:CISG, NASDAQ:HNSN, oil and gas, pharmaceutical, share, volume | Comments Off

What’s up Affymax, SuccessFactors and TearLab?

Posted on December 5, 2011 by Martin Timble

In this report: SuccessFactors (NYSE:SFSF), TearLab Corp. (NASDAQ:TEAR) and Affymax (NASDAQ:AFFY).

SuccessFactors (NYSE:SFSF) has soared by over 51 percent today after the company became the target of a $3.37 billion takeover by German enterprise applications software giant SAP. The offer …

Posted in Latest Headlines, Reports | Tagged AFFY, Affymax, Amgen, anemia, Apogen, Aranesp, cloud computing, company, concern, deal, drugs, FDA, Food and Drug Administration, investors, market leaders, NASDAQ:AFFY, NASDAQ:TEAR, NYSE:SFSF, Peginesatide, premium, quarter, safety, SAP, SFSF, share, stock, SuccessFactors, takeover, Target, TEAR, TearLab Corp., trading, treatment | Comments Off

What the fuss Focus Media, Gilead Sciences and Ship Finance International?

Posted on November 22, 2011 by Martin Timble

In this report: Focus Media Holding (NASDAQ:FMCN), Gilead Sciences (NASDAQ:GILD) and Ship Finance International (NYSE:SFL).

Focus Media Holding (NASDAQ:FMCN) rebounded by 8 percent today after plummeting on Monday following allegations from Muddy Waters that said the company had overstated the …

Posted in Latest Headlines, Reports | Tagged acquire, advertising, allegations, audit committee, banking, BMO Capital, company, deal, drugs, financials, FMCN, Focus Media Holding, funding, GILD, Gilead Sciences, healthcare, hepatitis C, loss, Muddy Waters, NASDAQ, NASDAQ:FMCN, NASDAQ:GILD, NYSE, NYSE:SFL, Outperform, overstated, Pharmasset, rating, report, revenue, SFL, shares, Ship Finance International, uncertainties | Comments Off

What’s up Inhibitex, Pharmasset and Global Education & Technology?

Posted on November 21, 2011 by Martin Timble

In this report: Global Education & Technology (NASDAQ:GEDU), Pharmasset (NASDAQ:VRUS) and Inhibitex (NASDAQ:INHX).

Global Education & Technology (NASDAQ:GEDU) rallied by more than 97 percent on during early trading on Monday after it was reported that British publishing group Pearson Plc. would …

Posted in Latest Headlines, Reports | Tagged acquire, agreed, biopharmaceutical, cash, CEO, China, deal, drugs, GEDU, Gilead Sciences, Global Education & Technology, growth, healthcare, hepatitis C, Inhibitex, INHX, investors, NASDAQ, NASDAQ:GEDU, NASDAQ:INHX, NASDAQ:VRUS, Pearson, Pharmasset, premium, publishing group, report, sector, shares, takeover, trading, VRUS | Comments Off

Earnings review (FRX, CHKP, OMC)

Posted on October 18, 2011 by Cameron White

In this report : Forest Laboratories Inc. (NYSE:FRX), Check Point Software Technologies (NASDAQ:CHKP) and Omnicom Group (NYSE:OMC).

Forest Laboratories Inc. (NYSE:FRX) traded over two percent lower on Tuesday after the company reported a 13 percent drop in second quarter profit. …

Posted in Top Post | Tagged analyst, Check Point Software Technologies, CHKP, company, drugs, earnings, Forest Laboratories Inc., FRX, NASDAQ:CHKP, net income, NYSE:FRX, NYSE:OMC, OMC, Omnicom Group, profit, profits, quarter, reported, revenue, spending, traded, Wall Street | Comments Off

What the Fuss Orexign Therapeutics, Northern Oil & Gas and AMR Corp.?

Posted on September 21, 2011 by Cameron White

In this report: Orexign Therapeutics (NASDAQ:OREX), Northern Oil and Gas (NYSE:NOG) and AMR Corp.(NYSE:AMR).

Orexign Therapeutics (NASDAQ:OREX) jumped more than 50 percent on Wednesday after it was announced that it would go to the Food and Drug Administration to get …

Posted in Latest Headlines, Reports | Tagged American Airlines, AMR, AMR Corp., approval, barrels, cardiovascular, Chad Mabry, clinical data, costs, diet-drug, drugs, Energy, FDA, flights, Food and Drug Administration, forecasting, fuel, Hurricane Irene, management, NASDAQ:OREX, NOG, Northern Oil and Gas, NYSE:AMR, NYSE:NOG, Oil, OREX, Orexign Therapeutics, outlook, price target, prices, profitable, quarter, rally, regulators, reserves, revenue, risks, Rodman & Renshaw, Wall Street | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.